TKI/BiTE Combo Extends Survival of Older Patients With Ph+ALL TKI/BiTE Combo Extends Survival of Older Patients With Ph+ALL

Estimated 3-year disease-free survival and overall survival rates topped 80% in elderly patients with Philadelphia-chromosome-positive ALL not amenable to chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news